<DOC>
	<DOC>NCT01353079</DOC>
	<brief_summary>The primary objective of this study is to demonstrate that SLIT administered pre-and co-seasonally is effective in reducing rhinoconjunctivitis symptoms during the entire short ragweed pollen season.</brief_summary>
	<brief_title>Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral Immunotherapy</brief_title>
	<detailed_description />
	<criteria>allergic to ragweed not allergic to ragweed history of anaphylaxis subject with chronic sinusitis, unstable angina, significant arrhythmia, uncontrolled hypertension, or other chronic or immunological disease Asthmatic subjects with FEV1 or PEF less than or equal to 80% predicted Subjects who have received experimental drug within 30 days prior to study admission Subjects who have received anitIgE medications in the last 12 months Subjects who have received ragweed immunotherapy in the last 3 years Subjects who are currently users of inhaled, intramuscular, or intravenous corticosteroids, tricyclic antidepressants, beta blockers, and MAO inhibitors Subjects refusing to sign epipen training form Females who are pregnant or breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>